<DOC>
	<DOCNO>NCT02590354</DOCNO>
	<brief_summary>HIV-1 infected patient normal peripheral blood CD4+ T-cell count undetectable viral load recruit four Belgian HIV reference center . Selected patient undergo two-step screen viral reservoir measurement perform among low viral reservoir analytical treatment interruption longstanding antiretroviral therapy ( ART ) . There randomization foreseen . Patients receive intense clinical laboratory follow-up 48 week follow 12 week post intervention .</brief_summary>
	<brief_title>Analytical Treatment Interruption HIV Positive Patients</brief_title>
	<detailed_description />
	<criteria>Able willing provide write informed consent Men woman age ≥ 18 &lt; 65 year . Confirmed HIV1 infection time prior study entry . Infected HIV1 subtype A , B , C , D , CRF01_AE CRF02_AG virus Participant take ART least 2 year baseline change ART regimen least 90 day prior study entry . ART regimen define mono bitherapy combination three active antiretroviral drug CD4 Tcell count &gt; = 500/μl period least 3 month prior study entry Nadir CD4+ Tcell count ≥300/μl . A low nadir CD4+ Tcell count allow measured time acute infection far relative CD4+ count remain 20 % . An acute infection define association clinical picture retroviral syndrome together seroconversion HIV serology incomplete confirmation test . Plasma viral load &lt; 50 copies/ml least 2 year baseline . ( Occasional `` blip '' permit happen six month study entry . An occasional blip define intermittent viremic episode viral load detection level 200 copies/ml return undetectable level next control ) . Willingness complete schedule assessment participant visit . Adequate peripheral vein access perform leukapheresis All female participant childbearing potential negative pregnancy test . These woman partner use double barrier contraception study . Females reproductive potential need negative serum urine pregnancy test screening . They define reach menopause postmenopausal least 24 consecutive month , menses within precede 24 month , woman undergo surgical sterilization , specifically hysterectomy , bilateral oophorectomy tubal ligation ) . NOTE : Acceptable documentation hysterectomy bilateral oophorectomy , bilateral salpingectomy , tubal microinserts , partner undergone vasectomy , menopause participantreported history . All participant must agree participate conception process ( e.g. , active attempt become pregnant , sperm donation , vitro fertilization ) . Previous current history AIDS defining event define category C 'Centers disease control prevention ( CDC ) ' clinical classification . Any acute infection serious medical illness within 60 day prior study entry . Participants exclude study serious illness ( require systemic treatment and/or admission ) subject either complete therapy clinically stable therapy , opinion Investigator , least 14 day prior study entry History resistance antiretroviral drug , document genotyping . Active hepatitis B C virus infection : define positive serology either disease sign active viral replication ? Significant risk HIV transmission treatment interruption opinion investigator . This include evidence unsafe sexual contact . Current past history cardiomyopathy significant ischemic cerebrovascular disease . History HIVrelated thrombocytopenia . Active renal disease ( defined glomerular filtration rate ( calculate MDRD equation ) 50 ml/min presence HIV associate nephropathy past medical history . Current known history cancer ( exception situ cervix carcinoma squamous cell carcinoma skin ) within five year prior screen . Pregnancy breastfeed . Any condition , include psychiatric psychological disorder might interfere adherence study requirement safety participant . Prior use HIV vaccine and/or nonestablished experimental therapy Any follow laboratory test result screen : 1 . Confirmed hemoglobin &lt; 11g/dl woman &lt; 12 g//dl men 2 . Confirmed platelet count &lt; 90,000/μl 3 . Confirmed neutrophil count &lt; 1200/μl 4 . Confirmed AST and/or ALT &gt; 5 x upper limit normal range ( ULN ) . One retest within 14 day allow . Receipt immune modulator suppressor within 30 day prior study entry , include , limited drug corticosteroid ( exception corticosteroid use topical use ) , granulocytemacrophage colonystimulating factor , interleukin ( IL ) 2 , IL7 IL15 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Participation interventional study involve investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treatment interruption</keyword>
	<keyword>functional cure</keyword>
</DOC>